{
  "id": 20744480,
  "title": "H.C. Wainwright reiterates Buy rating on Biogen stock at $270",
  "url": "https://urgent.news/2026/11/19/h-c-wainwright-reiterates-buy-rating-on-biogen-stock-at-270",
  "topic": "finance",
  "section": "Finance & Markets",
  "published": "2026-11-19T12:12:51.000Z",
  "source": {
    "name": "Investing.com",
    "slug": "investing-com",
    "url": "https://www.investing.com/news/analyst-ratings/hc-wainwright-reiterates-buy-rating-on-biogen-stock-at-270-93CH-5038656"
  },
  "original_language": "en",
  "account": "H.C. Wainwright has reaffirmed its Buy rating on Biogen Inc. (NASDAQ:BIIB) with a price target of $270.00 following the presentation of Phase 2 CELIA study data for diranersen at CTAD 2026. The stock, currently trading at $251.41, has risen 32% over the past six months and is 4% below its 52-week high. H.C. Wainwright noted that the Week 96 CELIA data demonstrated diranersen's benefits deepening with longer treatment, as the decline in the 60 mg twice-yearly arm slowed significantly, decreasing by 1.09 points on CDR-SB and 42% to 54% on ADAS-Cog-13 compared to the late-start group between Week 76 and Week 96. Plasma p-tau217 data indicated a roughly half reduction of the marker with no change in amyloid, suggesting potential combination with anti-amyloid approaches. The firm's analysis suggests that the 60 mg twice yearly dose may be optimal for Phase 3 trials, with the lowest rate of confusional state and consistent effects across endpoints. Biogen's recent strong third-quarter 2026 results, surpassing revenue and earnings expectations, have bolstered investor confidence. This growth is attributed to the company's robust growth portfolio, now accounting for 63% of its pharmaceutical revenues. Other analysts have also raised their price targets for Biogen, with Freedom Broker at $275 and Argus upgrading the stock to Buy. Despite these positive developments, potential headwinds are noted in the fourth quarter of 2026.",
  "summary": null,
  "key_points": [
    "H.C. Wainwright maintains Buy rating on Biogen stock",
    "$270 price target set for Biogen Inc. (BIIB)",
    "Phase 2 CELIA study data supports Biogen's diranersen"
  ],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}